← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 2.0% below its 1-year high (as of 2026-09-17). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 8.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
KYIV
Kyivstar Group Ltd.
Valuation N/A
Communication Services Risk 27 · Moderate
Price$13.61
Model IV—
P/IV—
Limited data — see page
KYMR
Kymera Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$114.96
Model IV—
P/IV—
Market implies +93.1%/yr vs model +2.0% · above model
KYN
Kayne Anderson Energy Infrastructure Fund, Inc.
Valuation N/A
Unknown
Price$14.84
Model IV—
P/IV—
Limited data — see page
KYNB
KYNTRA BIO, INC.
Valuation N/A
Healthcare Risk 63 · High
Price$7.97
Model IV—
P/IV—
Market implies +42.3%/yr vs model +2.0% · above model
KYTX
Kyverna Therapeutics, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$7.26
Model IV—
P/IV—
Limited data — see page
KZIA
KAZIA THERAPEUTICS LTD
Valuation N/A
Healthcare Risk 40 · Elevated
Price$11.19
Model IV—
P/IV—
Limited data — see page
LAB
STANDARD BIOTOOLS INC.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$0.69
Model IV—
P/IV—
Market implies +36.7%/yr vs model +2.0% · above model
LABT
Lakewood-Amedex Biotherapeutics Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$2.12
Model IV—
P/IV—
Limited data — see page
LAC
LITHIUM AMERICAS CORP.
Valuation N/A
Basic Materials Risk 31 · Moderate
Price$2.91
Model IV—
P/IV—
Market implies +54.1%/yr vs model +5.0% · above model
LAES
SEALSQ Corp
Valuation N/A
Technology Risk 44 · Elevated
Price$2.38
Model IV—
P/IV—
Market implies +79.7%/yr vs model +2.0% · above model
LAFA
LaFayette Acquisition Corp.
Valuation N/A
Financial Services Risk 37 · Moderate
Price$10.16
Model IV—
P/IV—
Limited data — see page
LAFAR
LaFayette Acquisition Corp.
Valuation N/A
Financial Services Risk 32 · Moderate
Price$0.08
Model IV—
P/IV—
Limited data — see page
LANV
Lanvin Group Holdings Ltd
Valuation N/A
Consumer Cyclical Risk 32 · Moderate
Price$1.10
Model IV—
P/IV—
Limited data — see page
LAR
Lithium Argentina AG
Valuation N/A
Basic Materials Risk 37 · Moderate
Price$5.85
Model IV—
P/IV—
Limited data — see page
LARK
LANDMARK BANCORP INC
Valuation N/A
Financial Services Risk 36 · Moderate
Price$32.47
Model IV—
P/IV—
Limited data — see page
LASR
NLIGHT, INC.
Valuation N/A
Technology Risk 31 · Moderate
Price$40.37
Model IV—
P/IV—
Market implies +47.2%/yr vs model +2.0% · above model
LATA
Galata Acquisition Corp. II
Valuation N/A
Financial Services
Price$10.19
Model IV—
P/IV—
Limited data — see page
LAWR
Robot Consulting Co., Ltd.
Valuation N/A
Technology Risk 49 · Elevated
Price$3.75
Model IV—
P/IV—
Limited data — see page
LB
LandBridge Co LLC
Valuation N/A
Financial Services Risk 51 · Elevated
Price$86.44
Model IV—
P/IV—
Limited data — see page
LBGJ
Li Bang International Corp Inc.
Valuation N/A
Industrials Risk 26 · Moderate
Price$2.25
Model IV—
P/IV—
Market implies +35.0%/yr vs model +2.0% · above model
LBRDA
Liberty Broadband Corp
Valuation N/A
Communication Services Risk 41 · Elevated
Price$35.99
Model IV—
P/IV—
Market implies +7.8%/yr vs model +15.0% · below model
LBRDK
Liberty Broadband Corp
Valuation N/A
Communication Services Risk 30 · Moderate
Price$36.02
Model IV—
P/IV—
Market implies +7.8%/yr vs model +15.0% · below model
LBRDP
Liberty Broadband Corp
Valuation N/A
Communication Services Risk 42 · Elevated
Price$22.13
Model IV—
P/IV—
Market implies +1.7%/yr vs model +15.0% · below model
LBRX
LB PHARMACEUTICALS INC
Valuation N/A
Healthcare Risk 39 · Moderate
Price$44.84
Model IV—
P/IV—
Limited data — see page
LC
LendingClub Corp
Valuation N/A
Financial Services Risk 40 · Elevated
Price$19.21
Model IV—
P/IV—
Market implies +65.7%/yr vs model +5.1% · above model
LCCC
Lakeshore Acquisition III Corp.
Valuation N/A
Financial Services Risk 37 · Moderate
Price$10.53
Model IV—
P/IV—
Limited data — see page
LCCCR
Lakeshore Acquisition III Corp.
Valuation N/A
Financial Services Risk 37 · Moderate
Price$0.15
Model IV—
P/IV—
Limited data — see page
LCFY
Locafy Ltd
Valuation N/A
Technology Risk 37 · Moderate
Price$2.44
Model IV—
P/IV—
Limited data — see page
LCID
Lucid Group, Inc.
Valuation N/A
Consumer Cyclical Risk 50 · Elevated
Price$4.22
Model IV—
P/IV—
Market implies +62.7%/yr vs model +8.0% · above model
LCLN
Lincoln International, Inc.
Valuation N/A
Financial Services
Price$26.81
Model IV—
P/IV—
Limited data — see page
LCTX
Lineage Cell Therapeutics, Inc.
Valuation N/A
Healthcare Risk 29 · Moderate
Price$1.01
Model IV—
P/IV—
Market implies +28.1%/yr vs model +35.3% · below model
LDI
loanDepot, Inc.
Valuation N/A
Financial Services Risk 48 · Elevated
Price$0.84
Model IV—
P/IV—
Market implies -17.3%/yr vs model +2.0% · below model
LDP
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc.
Valuation N/A
Unknown
Price$19.95
Model IV—
P/IV—
Limited data — see page
LEE
LEE ENTERPRISES, Inc
Valuation N/A
Communication Services Risk 73 · High
Price$7.69
Model IV—
P/IV—
Market implies +25.5%/yr vs model +0.0% · above model
LEGN
Legend Biotech Corp
Valuation N/A
Healthcare Risk 36 · Moderate
Price$18.64
Model IV—
P/IV—
Limited data — see page
LEGO
Legato Merger Corp. IV
Valuation N/A
Financial Services Risk 36 · Moderate
Price$10.00
Model IV—
P/IV—
Limited data — see page
LEGT
Legato Merger Corp. III
Valuation N/A
Financial Services Risk 35 · Moderate
Price$9.52
Model IV—
P/IV—
Limited data — see page
LENZ
LENZ Therapeutics, Inc.
Valuation N/A
Healthcare Risk 32 · Moderate
Price$4.23
Model IV—
P/IV—
Market implies +26.5%/yr vs model +15.0% · above model
LEO
BNY MELLON STRATEGIC MUNICIPALS, INC.
Valuation N/A
Unknown
Price$5.92
Model IV—
P/IV—
Limited data — see page
LEU
CENTRUS ENERGY CORP
Valuation N/A
Basic Materials Risk 53 · Elevated
Price$146.25
Model IV—
P/IV—
Market implies +42.3%/yr vs model +8.0% · above model
LEXX
Lexaria Bioscience Corp.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$3.21
Model IV—
P/IV—
Market implies +77.1%/yr vs model +2.0% · above model
LFAC
Leapfrog Acquisition Corp
Valuation N/A
Financial Services
Price$10.07
Model IV—
P/IV—
Limited data — see page
LFWD
Lifeward Ltd.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$7.12
Model IV—
P/IV—
Market implies +33.8%/yr vs model +2.0% · above model
LGCL
Lucas GC Ltd
Valuation N/A
Technology Risk 33 · Moderate
Price$3.15
Model IV—
P/IV—
Market implies -50.0%/yr vs model +15.0% · below model
LGHL
Lion Group Holding Ltd
Valuation N/A
Financial Services Risk 50 · Elevated
Price$8.30
Model IV—
P/IV—
Limited data — see page
LGI
LAZARD GLOBAL TOTAL RETURN & INCOME FUND INC
Valuation N/A
Unknown
Price$17.47
Model IV—
P/IV—
Limited data — see page
LGN
Legence Corp.
Valuation N/A
Industrials
Price$56.65
Model IV—
P/IV—
Limited data — see page
LGND
LIGAND PHARMACEUTICALS INC
Valuation N/A
Healthcare Risk 54 · Elevated
Price$284.47
Model IV—
P/IV—
Market implies +36.2%/yr vs model +2.6% · above model
LGO
Largo Inc.
Valuation N/A
Basic Materials Risk 27 · Moderate
Price$0.68
Model IV—
P/IV—
Limited data — see page
LGPS
LOGPROSTYLE INC.
Valuation N/A
Industrials Risk 58 · Elevated
Price$0.83
Model IV—
P/IV—
Limited data — see page
LGVN
Longeveron Inc.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$7.33
Model IV—
P/IV—
Market implies +150.0%/yr vs model +14.1% · above model
LHSW
Lianhe Sowell International Group Ltd
Valuation N/A
Technology Risk 31 · Moderate
Price$0.62
Model IV—
P/IV—
Market implies -47.7%/yr vs model +50.0% · below model
LICN
Lichen International Ltd
Valuation N/A
Industrials Risk 28 · Moderate
Price$1.04
Model IV—
P/IV—
Market implies +36.1%/yr vs model +2.0% · above model
LIDR
AEye, Inc.
Valuation N/A
Consumer Cyclical Risk 27 · Moderate
Price$1.21
Model IV—
P/IV—
Market implies +45.3%/yr vs model +8.0% · above model
LIEN
Chicago Atlantic BDC, Inc.
Valuation N/A
Unknown Risk 42 · Elevated
Price$10.18
Model IV—
P/IV—
Limited data — see page
LILA
Liberty Latin America Ltd.
Valuation N/A
Communication Services Risk 54 · Elevated
Price$8.81
Model IV—
P/IV—
Limited data — see page
LIMN
Liminatus Pharma, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$3.47
Model IV—
P/IV—
Limited data — see page
LINC
LINCOLN EDUCATIONAL SERVICES CORP
Valuation N/A
Consumer Defensive Risk 42 · Elevated
Price$25.02
Model IV—
P/IV—
Limited data — see page
LITE
Lumentum Holdings Inc.
Valuation N/A
Technology Risk 57 · Elevated
Price$838.96
Model IV—
P/IV—
Market implies +83.9%/yr vs model +2.0% · above model
LITS
Lite Strategy, Inc.
Valuation N/A
Healthcare Risk 28 · Moderate
Price$1.11
Model IV—
P/IV—
Market implies -22.3%/yr vs model +15.0% · below model